Download fulltext HTML

https://doi.org/10.18502/espoch.v3i1.14486

statistics

  • 157 Abstract Views
  • 51 PDF Views
  • 0 HTML Views

authors

  • TV Carpio Arias

    TV Carpio Arias

    Professor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador
    https://orcid.org/0000-0003-2989-1751
  • RC Saeteros Hernández

    RC Saeteros Hernández

    Professor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador
  • P Herrera Cisneros

    P Herrera Cisneros

    Professor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador
  • GR Inca Ruiz

    GR Inca Ruiz

    Professor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador

Published Date

  • Nov 9, 2023

Post-vaccination Symptoms with Second Dose of AstraZeneca in a Sample of Immunized Population of Ecuadorian Public Servants

ESPOCH Congresses: The Ecuadorian Journal of S.T.E.A.M. / Volume 3 Issue 1 / Pages 780–792

Abstract

Since AstraZeneca is a new vaccine against SARSCOV2, it should be monitored worldwide. This study presents the adverse reactions caused by the second dose of the AstraZeneca vaccine. Thequantitative, descriptive, cross-sectional research used a validated survey conducted on 428 public staff who were vaccinated with the second dose of the ChAdOx1-S vaccine at the Escuela Superior Politécnica de Chimborazo, the results were processed in Jamovi. 289 respondents reported having symptoms after inoculation, women (13.15%) presented more symptoms than men (7.27%). Most of the symptoms, both local and systemic, were mild and subsided with the administration of oral analgesics and lasted up to three days in 50% of the cases. AstraZeneca’s vaccine proves to be a safe biologic vaccine to generate antibodies against SARSCOV” in the adult population, and its use is therefore recommended.


Keywords: drug-related side effects and adverse reactions, coronavirus infections, pharmacovigilance


Resumen


Introducción: Dado que se trata de una nueva vacuna contra el SARSCOV2, debe ser monitoreada a nivel mundial, el presente estudio presenta las reacciones adversas presentadas con la segunda dosis de la vacuna AstraZeneca. Materiales y Métodos: La presente investigación cuantitativa, descriptiva, transversal, utilizó una encuesta validada aplicada a 428 funcionarios públicos que fueron vacunados con la segunda dosis de la vacuna ChAdOx1- S en la Escuela Superior Politécnica de Chimborazo, los resultados fueron procesados en Jamovi . Resultados: 289 encuestados informaron tener síntomas después de la inoculación, las mujeres (13,15%) presentaron más síntomas que los hombres (7,27%). La mayoría de los síntomas, tanto locales como sistémicos, fueron leves y cedieron con la administración de analgésicos orales y duraron hasta tres días en el 50% de los casos. Conclusiones: La vacuna de AstraZeneca demuestra ser una vacuna biológica segura para generar anticuerpos frente al SARSCOV” en la población adulta, por lo que se recomienda su uso.


Palabras Clave: kwd2.

References
[1] Wu Y, Chen C, Chan Y. The outbreak of COVID-19: An overview [Internet]. Journal of the Chinese Medical Association. Wolters Kluwer Health. 2020 [cited 2022 Jun 20];83:217–220. Available from: https://journals.lww.com/jcma/fulltext/2020/03000/ The_outbreak_of_COVID_19__An_overview.3.aspx

[2] Zhou P. Yang Xlou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020 Mar 12 [cited 2022 Jun 20];579(7798):270–273. Available from: https://www.nature.com/articles/s41586-020-2012-7.pdf

[3] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [Internet]. International Journal of Antimicrobial Agents. 2020 Mar;55(3):105924. [cited 2022 Jun 20] Available from: https://www.sciencedirect. com/science/article/pii/S0924857920300674?via%3Dihub

[4] Inca-Ruiz P, Inca-León A. Evolution of coronavirus disease (COVID-19) in Ecuador. Science at the Service of Health [Internet]. 2020 Apr 12 [cited 2022 Jun 21];11(1):5– 15. Available from: http://revistas.espoch.edu.ec/index.php/cssn/article/view/441/422

[5] Esparza J, Vizcaino G, Pujol FH. Thrombosis associated with vaccines against Covid-19 based on adenoviral vectors: Implications for vaccination in Venezuela. CientMed [Internet]. 2021 May 21 [cited 2022 Jun 20];2(28):1–7. Available from: https://drive.google.com/file/d/1UtN6T_B2i7sv8fhWC0Q5QTi2c7dwtVI_/view

[6] Cerón G. Vaccines against COVID 19: A short-term view. UTA Medicines [Internet]. 2022 [cited 2022 Jun 20];6(1):1–2. Available from: https://revistas.uta.edu.ec/erevista/index.php/medi/article/view/1556/1307

[7] Pan American Health Organization. Frequently asked questions about vaccines against COVID-19 [Internet]. Washington DC: PAHO/WHO; 2022 [cited 2022 Jun 20]. Available from: https://iris.paho.org/bitstream/handle/10665.2/55751/ OPSFPLIMCOVID19220004_spa.pdf?sequence=5&isAllowed=y

[8] Piebald JJ. Vaccine against COVID-19 [Internet]. Spanish Journal of Chemotherapy. Spanish Society of Chemotherapy; 2021 [cited 2022 Jun 20];34569–598. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638770/

[9] Casas I, Mena G. [The COVID-19 vaccination,Internet]. Medicina Clínica (Barc). 2021 May;156(10):500–502. [cited 2022 Jun 20]

[10] Gaus D. COVID-19: Vaccines. Rural family practice [Internet]. 2021 Mar 29 [cited 2022 Jun 20];6(1). Available from: https://dialnet.unirioja.es/descarga/articulo/7898556.pdf eleven.

[11] 11 Deloria Knoll M, Wonodi C. Comment Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet [Internet]. 2021 [cited 2022 Jun 24];397:72–4. Available from:https://pubmed.ncbi.nlm.nih.gov/33306990/

[12] Iacobucci G. Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show [Internet]. BMJ. 2021 Apr;373(1068):n1068. [cited 2022 Jun 20] Available from: https://www.bmj.com/content/373/bmj.n1068

[13] Ministry of Health. Vaccine sheet against SARS-COV-2 vaccine AZD1222- Astrazeneca Laboratory [Internet]. Santiago de Chile; 2021 Apr [cited 2022 Jun 20]. Available from: https://www.minsal.cl/wp-content/uploads/2021/04/FICHAASTRAZENECA. pdf

[14] Sabillón LM, Reyes OF, Cabrera CA. Frequency of adverse events due to anticovid vaccines in the department of Atlántida, Honduras. Innovare: Science and technology magazine [Internet]. 2021 Dec 15 [cited 2022 Jun 20];10(3):126–130. Available from: https://www.camjol.info/index.php/INNOVARE/article/view/12987/15051 fifteen.

[15] Castelo-Rivas P, Ruiz-Ortega J, Valencia-Pallaroso M. Clinical manifestations post vaccination with AstraZeneca in teachers of the Emilio Lorenzo Stehle Educational Unit Clinical manifestations post vaccination with AstraZeneca in teachers of Emilio Lorenzo Stehle School. [cited 2022 Jun 20]; Available from: http://revistaamc.sld.cu/index.php/amc/article/view/8819

[16] Adelaida S. Vaccination alternatives for children under 60 years of age with a first dose of Astra-Zeneca (05/10/2021 | Policy Commons [Internet]. 2021. Barcelona; 2021 May [cited 2022 Jun 20]. Available from: https://policycommons.net/artifacts/2080343/alternativas-de-vacunacion-paramenores- de-60-anos-con-una-primera-dosis-de-astra-zeneca-10052021/2835641/

[17] Babaee E, Amirkafi A, Tehrani-Banihashemi A. SoleimanvandiAzar N, Eshrati B, Rampisheh Z, et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases [Internet]. 2022 May 18 [cited 2022 Jun 20];22:476. Available from: https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-022-07411- 5.pdf

[18] Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARSCoV- 2 Spike Protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: Lack of association with age, sex, obesity, and adverse reactions [Internet]. Frontiers in Immunology. 2021 Nov;12(779212):779212. [cited 2022 Jun 20] Available from: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932623-4

[19] Rios-González C, Mendez J, Estigarribia G, Aguilar G, Martínez P. Side effects of anti-COVID-19 vaccines in Paraguayan health personnel: An exploratory study. Rev Parag Public Health [Internet]. 2021 [cited 2022 Jun 24];11(2):24–29. Available from:http://scielo.iics.una.py/pdf/rspp/v11n2/2307-3349-rspp-11-02-24.pdf

[20] Leones H, Guzmán C. Vaccination against SARS-COV-2: side effects of the CHADOX1NCOV-19 vaccine (AstraZeneca). Sapienza [Internet]. 2022 Jun 14 [cited 2022 Jun 20];3(3):183–93. Available from:https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/402/263

[21] Tequare MH, Abraha HE, Adhana MT, Tekle TH, Belayneh EK, Gebresilassie KB, et al. Adverse events of Oxford/AstraZeneca’s COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Regions [Internet]. 2021 Dec [cited 2022 Jun 24];1:124–9. Available from: https: //www.sciencedirect.com/science/article/pii/S2772707621000266

[22] Becker MS, Sofía Becker M, Balbuena C, Samudio M. Post-vaccination adverse reactions and eventual Covid-19 infection in dentists. Revista Ciencias de la Salud [Internet]. 2021 [cited 2022 Jun 20];3(2):85–94. Available from: https://docs.bvsalud. org/biblioref/2021/12/1349330/ao11_vol3n2.pdf

[23] Galván-Casas C, Català A, Muñoz-Santos C. SARS-CoV-2 vaccines and the skin [Internet]. Actas Dermo-Sifiliográficas. 2021 Oct;112(9):828–36. [cited 2022 Jun 20] Available from: https://reader.elsevier.com/reader/sd/pii/S0001731021002039?token= 03D66E252F80E2DD4426BC80CC71C89F47B3BECEDFDAAA74A7FCDD95CCF5DF1A703E194B782392BA0C948AC2D844382F&us-east-1&originCreation=20220621230059

[24] World Health Organization. Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 [Internet]. 2022 Mar [cited 2022 Jun 23]. Available from: https://apps.who.int/iris/bitstream/handle/10665/352467/ WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222-annexes-2022. 1-eng.pdf?sequence=1&isAllowed=y

[25] World Health Organization. COVID-19 ChAdOx1-S vaccine [recombinant,Internet]. Geneva; 2021 May [cited 2022 Jun 25]. Available from: https://www.who.int/docs/ default-source/coronaviruse/act-accelerator/covax/21099_spanish_astrazeneca_ vaccine-explainer.pdf?sfvrsn=f7250720_5#:$\sim$:text=ChAdOx1%20nCoV% 2D19%20(Recombinant)%5D&text=The%20vaccine%20ChAdOx1%2DS%2FnCoV, coronavirus%202019%20(COVID%2019).